接受别嘌醇治疗的痛风患者中双能CT显示单钠尿酸盐晶体沉积的存在情况
该前瞻性研究纳入152例接受别嘌醇≥300 mg/日平均5.1年的痛风患者,用双能CT评估晶体沉积。69.1%的患者存在晶体沉积,中位总体积0.16 cm3;无 palpable 痛风石且sUA<6.0 mg/dL者沉积率为46.9%,sUA≥6.0 mg/dL且有痛风石者达90.0%。晶体体积与sUA≥6.0 mg/dL、近3个月痛风发作及痛风石正相关。
要点
- 接受别嘌醇≥300 mg/日平均5.1年的痛风患者中69.1%经双能CT仍见单钠尿酸盐晶体沉积。
- 无 palpable 痛风石且sUA<6.0 mg/dL者晶体沉积率为46.9%,sUA≥6.0 mg/dL且有痛风石者为90.0%。
- 晶体总体积与sUA≥6.0 mg/dL、近3个月痛风发作及痛风石正相关,并与患者总体疾病活动印象评分正相关。
核心结论
- 相当比例无 palpable 痛风石的痛风患者尽管接受别嘌醇≥300 mg/日相当长时间,仍存在单钠尿酸盐晶体沉积。
- sUA较高且具有严重疾病临床特征的患者,单钠尿酸盐晶体沉积的频率更高、体积更大。
研究设计与样本
- 前瞻性研究,从美国和纽西兰招募接受别嘌醇≥300 mg/日至少3个月的痛风患者,采用监测入组使约25%为可触及痛风石患者、约50%血清尿酸盐<6.0 mg/dL(<357 µmol/L)。
- 共纳入152例接受别嘌醇≥300 mg/日平均5.1年的患者,用双能CT双侧测量手/腕、足/踝/跟腱和膝的单钠尿酸盐晶体沉积,并按sUA水平和痛风特征分析。
主要发现
- 152例患者中69.1%双能CT显示晶体沉积,中位晶体总体积0.16 cm3(范围0.01-19.53 cm3)。
- 晶体沉积率从sUA<6.0 mg/dL且无可触及痛风石者的46.9%到sUA≥6.0 mg/dL且有痛风石者的90.0%。
- 晶体沉积总体积与sUA≥6.0 mg/dL、近3个月痛风发作及痛风石正相关。
- 晶体沉积总体积与患者总体疾病活动印象评分正相关。
关键数值与推荐
- 入组条件为接受别嘌醇≥300 mg/日至少3个月。
- 监测入组目标为约25%可触及痛风石患者和约50%血清尿酸盐<6.0 mg/dL(<357 µmol/L)患者。
- sUA<6.0 mg/dL且无可触及痛风石者晶体沉积率为46.9%,sUA≥6.0 mg/dL且有痛风石者为90.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dual-energy CT (DECT) detects and quantifies monosodium urate (MSU) crystal deposition with high precision. This DECT study assessed crystal deposition in patients with gout treated with stable-dose allopurinol, and investigated potential clinical determinants for crystal deposition. METHODS: Patients with gout treated with allopurinol ≥300 mg daily for at least 3 months were prospectively recruited from the USA and New Zealand, using monitored enrolment to include approximately 25% patients with palpable tophi and approximately 50% with serum urate (sUA) levels <6.0 mg/dL (<357µmol/L). MSU crystal deposition was measured in the hands/wrists, feet/ankles/Achilles and knees bilaterally. The presence and total volume of crystals were assessed by DECT and analysed according to sUA levels and gout characteristics. RESULTS: Among 152 patients receiving allopurinol ≥300 mg/day for 5.1 years on average, 69.1% had crystal deposition on DECT, with a median total crystal volume of 0.16 cm3 (range: 0.01-19.53 cm3). The prevalence of crystal deposition ranged from 46.9% among patients with sUA <6.0 mg/dL and no palpable tophi to 90.0% among those with sUA ≥6.0 mg/dL and tophi. Total volume of crystal deposition was positively associated with sUA ≥6.0 mg/dL, gout flares within the past 3 months and tophi. Total volume of crystal deposition correlated positively with Patient Global Impression of Disease Activity scores. CONCLUSION: A substantial proportion of patients without palpable tophi have MSU crystal deposition, despite receiving allopurinol doses ≥300 mg/day for a considerable duration. Patients with higher sUA and clinical features of severe disease have a higher frequency and greater volume of MSU crystal deposition.
引用
- Dalbeth N, Nicolaou S, Baumgartner S, et al. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Ann Rheum Dis. 2017. PMID: 29146741. doi:10.1136/annrheumdis-2017-212046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。